News & Updates
Showing Pharmacy articles
Showing

Post-transplant KRd a new SoC for MM?
In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Empagliflozin improves outcomes in HFpEF patients regardless of age
Treatment with empagliflozin results in a reduction in heart failure (HF) risk and renal outcomes and in better health-related quality of life (HRQoL) among patients with chronic HF with preserved ejection fraction (HFpEF), a study has shown. In addition, the study drug is well tolerated by older patients.

Vedolizumab appears safe, effective in first-line treatment of ulcerative colitis in children
Children with ulcerative colitis seem to respond well to vedolizumab in the first-line setting, inducing remission without increasing the risk of adverse events, according to a small study.

PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.





